Key facts
- This page summarizes Matthew Richard Moore's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 10 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 15 Feb 2024, 18:47.
Matthew Richard Moore - 13 Feb 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- SVP and Chief Business Officer
- Issuer ticker
- ARQT
- Reported as of
- 13 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Feb 2024, 18:47:43 UTC
- Prior SEC filing
- 17 Jan 2024
- Next SEC filing
- 06 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John W. Smither, Attorney-in-Fact for Matthew Richard Moore
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Richard Moore filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 15 Feb 2024.
Change
- Previous filing in this sequence was filed on 17 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +26,666
- Change %
- +49%
- Price
- Shares after
- 81,256
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +26,666
- Change %
- +33%
- Price
- Shares after
- 107,922
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +17,650
- Change %
- +16%
- Price
- Shares after
- 125,572
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +19,750
- Change %
- +16%
- Price
- Shares after
- 145,322
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F3
ARQT
transaction
Common Stock
Award
- Transaction value
- Shares
- +4,166
- Change %
- +2.9%
- Price
- Shares after
- 149,488
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARQT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $28.72
- Footnotes
- F1, F5
ARQT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $28.72
- Footnotes
- F1, F6
ARQT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -35,300
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,300
- Exercise price
- $17.67
- Footnotes
- F2, F7
ARQT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -39,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,500
- Exercise price
- $15.82
- Footnotes
- F3, F8
ARQT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,500
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 13 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $28.72
- Footnotes
- F4, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024.
Footnote F2
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
Footnote F3
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024.
Footnote F4
On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, performance-based option granted to the Reporting Person on January 19, 2021, and deemed earned on August 29, 2023, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
Footnote F5
The canceled option vested as to 1/4 of the total shares on July 20, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on July 20, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F6
The canceled option vested as to 1/4 of the total shares on January 11, 2022, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on January 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F7
The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F8
The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F9
The canceled option vested as to 1/48 of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.